论文部分内容阅读
目的探讨尿激酶型纤溶酶原激活物和生存素在乳腺癌中的表达相关性及其临床意义。方法应用免疫组织化学SABC法检测97例原发性乳腺癌患者中尿激酶型纤溶酶原激活物(uPA)及survivin的表达。结果在97例乳腺癌患者中,uPA阳性表达者占49%(48/97);survivin阳性表达者35%(34/97)。uPA的表达与survivin呈正相关(r=0.224)。uPA阳性率在无淋巴结转移组和浸润型乳腺癌组明显高于有淋巴结转移组和非浸润组(P<0.05)。结论 uPA和survivin在乳腺癌中的表达率较高,提示uPA和survivin在乳腺癌的发生、发展中起重要作用,且两者的表达有一定的相关性,检测它们对临床诊断和靶向治疗有指导意义。
Objective To investigate the correlation between the expression of urokinase-type plasminogen activator and survivin in breast cancer and its clinical significance. Methods The expression of urokinase-type plasminogen activator (uPA) and survivin in 97 cases of primary breast cancer was detected by immunohistochemical SABC method. Results In 97 cases of breast cancer, uPA positive expression accounted for 49% (48/97); survivin positive expression was 35% (34/97). The expression of uPA was positively correlated with survivin (r = 0.224). The positive rate of uPA in non-lymph node metastasis group and invasive breast cancer group was significantly higher than that in lymph node metastasis group and non-invasive group (P <0.05). Conclusion The high expression of uPA and survivin in breast cancer suggests that uPA and survivin play an important role in the occurrence and development of breast cancer. The expression of uPA and survivin is correlated with clinical diagnosis and targeted therapy Instructive.